Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

Paolo A. Ascierto, Kim Margolin

Research output: Contribution to journal › Editorial

29 Scopus citations

Access to Document

@article{fe786085b28f44fc88c21df2b7ef7d21,

title = "Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma",

author = "Ascierto, {Paolo A.} and Kim Margolin",

year = "2014",

month = jun,

day = "1",

doi = "10.1002/cncr.28622",

language = "English",

volume = "120",

pages = "1617--1619",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

AU - Ascierto, Paolo A.

AU - Margolin, Kim

PY - 2014/6/1

Y1 - 2014/6/1

UR - http://www.scopus.com/inward/record.url?scp=84901358299&partnerID=8YFLogxK

U2 - 10.1002/cncr.28622

DO - 10.1002/cncr.28622

M3 - Editorial

C2 - 24577788

AN - SCOPUS:84901358299

SN - 0008-543X

VL - 120

SP - 1617

EP - 1619

JO - Cancer

JF - Cancer

IS - 11

ER -